StockNews.com Upgrades Prestige Consumer Healthcare (NYSE:PBH) to Buy

Prestige Consumer Healthcare (NYSE:PBH) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Tuesday.

Other analysts have also issued reports about the company. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a report on Monday, December 9th. Jefferies Financial Group restated a “hold” rating and set a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. Finally, DA Davidson reiterated a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of “Moderate Buy” and a consensus price target of $85.25.

Prestige Consumer Healthcare Price Performance

PBH stock opened at $74.45 on Tuesday. The company has a market capitalization of $3.68 billion, a PE ratio of 18.11, a P/E/G ratio of 2.32 and a beta of 0.51. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. The stock’s 50 day moving average is $80.53 and its two-hundred day moving average is $74.17. Prestige Consumer Healthcare has a 52-week low of $58.22 and a 52-week high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.09. The firm had revenue of $283.79 million for the quarter, compared to analysts’ expectations of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The firm’s quarterly revenue was down .9% on a year-over-year basis. During the same period in the prior year, the company posted $1.07 earnings per share. Analysts predict that Prestige Consumer Healthcare will post 4.44 earnings per share for the current fiscal year.

Insider Transactions at Prestige Consumer Healthcare

In related news, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the transaction, the chief executive officer now owns 320,952 shares in the company, valued at $26,510,635.20. This trade represents a 3.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Adel Mekhail sold 9,063 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total transaction of $743,166.00. Following the sale, the executive vice president now owns 18,365 shares in the company, valued at $1,505,930. This represents a 33.04 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 38,810 shares of company stock valued at $3,187,300. Company insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Arizona State Retirement System lifted its position in shares of Prestige Consumer Healthcare by 1.9% in the second quarter. Arizona State Retirement System now owns 13,900 shares of the company’s stock worth $957,000 after purchasing an additional 264 shares in the last quarter. Quest Partners LLC increased its stake in shares of Prestige Consumer Healthcare by 2,826.7% in the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after acquiring an additional 424 shares during the last quarter. Choreo LLC acquired a new stake in Prestige Consumer Healthcare during the second quarter valued at $677,000. BOKF NA grew its stake in Prestige Consumer Healthcare by 120.9% in the second quarter. BOKF NA now owns 7,584 shares of the company’s stock valued at $522,000 after purchasing an additional 4,150 shares in the last quarter. Finally, GHP Investment Advisors Inc. raised its stake in shares of Prestige Consumer Healthcare by 1.1% during the 2nd quarter. GHP Investment Advisors Inc. now owns 86,540 shares of the company’s stock worth $5,958,000 after purchasing an additional 928 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.